Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Proteon Therapeutics logo — Pioneering medical advancements to improve renal and vascula...

Proteon Therapeutics

Pioneering medical advancements to improve renal and vascular health through innovative tissue remodeling techniques.

Founded 2001 Post-IPO Equity Total: $188.54M Biotechnology, Pharmaceutical

General Information

Company Name Proteon Therapeutics
Founded Year 2001
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Proteon Therapeutics. To contact Proteon Therapeutics, visit proteontherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Proteon Therapeutics compare?

A PDF of Proteon Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Proteon Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Proteon Therapeutics

Proteon Therapeutics, Inc is a biopharmaceutical company founded in 2001, pioneering medical advancements to improve renal and vascular health through innovative tissue remodeling techniques. The company is focused on developing pharmaceuticals for patients with renal and vascular diseases. Proteon Therapeutics leverages a unique understanding of tissue remodeling to build a pipeline of proprietary therapeutics. Their first drug candidate, PRT-201, aims to improve blood flow following vascular surgery procedures. The company's clinical efforts are initially concentrated on vascular access for hemodialysis and peripheral arterial disease (PAD). Proteon Therapeutics recently secured a €21.00M Post-IPO Equity investment on 10 August 2021, with funding from Seventure Partners, Aqua-Spark, Montis Capital, LLC, PFR Life Science, and Nutreco. As the company remains at the forefront of biotechnological advancements in the Biotechnology and Pharmaceutical industries, this investment will likely further propel their research and development efforts, positioning Proteon Therapeutics to make significant contributions to the advancement of medical treatments for renal and vascular diseases.

Business keywords: biopharmaceutical, renal disease, vascular disease, tissue remodeling, proprietary therapeutics, drug development, PRT-201, vascular surgery, hemodialysis, peripheral arterial disease (PAD)

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €21.00M 5
Seventure Partners Aqua-Spark Montis Capital, LLC
Seventure Partners, Aqua-Spark +3
10 Aug 2021
Grant Undisclosed -
25 Jul 2019
Post IPO Equity $22.00M 1
Deerfield
22 Jun 2017
Series D $45.00M 10
Intersouth Partners MPM Capital Skyline Ventures
Intersouth Partners, MPM Capital +8
16 May 2014
Venture Round $4.34M -
19 Feb 2014
Series C $15.20M 8
Bessemer Venture Partners Intersouth Partners MPM Capital
Bessemer Venture Partners, Intersouth Partners +6
12 Aug 2011
Series B $50.00M 9
Bessemer Venture Partners Intersouth Partners MPM Capital
Bessemer Venture Partners, Intersouth Partners +7
28 May 2009
Series A $12.00M 6
Bessemer Venture Partners Intersouth Partners Skyline Ventures
Bessemer Venture Partners, Intersouth Partners +4
06 Sep 2007
Series A $19.00M 4
Intersouth Partners Skyline Ventures TVM Capital
Intersouth Partners, Skyline Ventures +2
30 Mar 2006

Proteon Therapeutics Alternatives & Competitors

View All Alternatives
Proteon Therapeutics vs
Reven Pharmaceuticals
Reven Pharmaceuticals United States

Diligently pursuing scientific innovation to exponentially improve health and well-being.

Series D
14 employees
Biotechnology, Health Care
Proteon Therapeutics vs
Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. United States

Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders

Post-IPO Equity
13 employees
Biotechnology, Health and Wellness
Proteon Therapeutics vs
Lumos Pharma
Lumos Pharma United States

Transforming Lives with Rare Focus

Series B
47 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Proteon Therapeutics

Pioneering medical advancements to improve renal and vascular health through innovative tissue remodeling techniques.
Proteon Therapeutics was founded in 2001.
Proteon Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical, renal disease, vascular disease and tissue remodeling.
Proteon Therapeutics has completed 9 funding rounds, raising a total of $188.54M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Proteon Therapeutics include Reven Pharmaceuticals, Allena Pharmaceuticals, Inc., Lumos Pharma, Aro Biotherapeutics, Dunad Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Proteon Therapeutics and Reven Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Proteon Therapeutics, https://bouncewatch.com/company/proteon-therapeutics, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout